Discover how Chroma is expanding our impact.
ASGCT 2023: Development of a human PCSK9-targeting epigenetic editor with durable, near-complete in vivo silencing
ASGCT 2023: Multiplexed editing without chromosomal rearrangements using epigenetic editors
Chroma Medicine Announces Data Demonstrating the Benefits of Epigenetic Editing for Multiplex Gene Regulation at ASGCT 2023
Boston, MA, May 19, 2023 – Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today presented data demonstrating the advantages of epigenetic editing for multiplex gene regulation at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting in Los Angeles. Chroma’s epigenetic editing platform harnesses the cell’s endogenous mechanism for regulating gene expression to durably modulate transcription without cutting or nicking the DNA, offering a potentially safer approach for multiplex editing. This avoids challenges associated with gene editing methods that rely upon DNA breaks to alter gene expression, which have the potential…
Chroma Medicine Presents Data Demonstrating Near-Complete, Durable In Vivo Silencing with Targeted Epigenetic Editors at 2023 ASGCT Annual Meeting
Boston, MA, May 18, 2023 – Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced in vivo data that demonstrate 99% silencing of two distinct targets and compelling proof-of-concept for its epigenetic editing platform. The data presented at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting showcase the rapid advancement of the company’s programs and platform. The work describes the development of Chroma’s epigenetic editor targeting PCSK9, a well-characterized genetic target for addressing hyperlipidemia. The company’s epigenetic editor showed highly effective, durable, and specific silencing of PCSK9 in a transgenic…